Pipeline Therapies : Focus on B Cell (and Plasma Cell) Depletion

Description

In a recent presentation, Richard Furie reflects on the evolution of treatment for systemic lupus erythematosus (SLE) over the past 30 years, highlighting the journey from just two drugs in development to a current landscape teeming with potential therapies. He discusses the critical role of B cells in SLE, especially focusing on the CD20 molecule and its implications for treatment.



Furie reminisces about the failed LUNAR study but emphasizes its educational value, noting that studies suggest better clinical outcomes are associated with complete B cell depletion. He critiques previous approaches, suggesting that combining drugs like rituximab and belimumab might not be enough and introduces obinutuzumab, a more effective CD20-targeting antibody, as a potential game changer for achieving greater B cell depletion and improved patient responses.



During his analysis of the NOBILITY trial, Furie shares data indicating a more significant depletion of B cells with obinutuzumab compared to rituximab and discusses the resultant enhanced clinical responses observed in patients. He notes the nuances of defining treatment success in trials, including kidney function measures that some might consider too strict. Furie acknowledges the potential ceiling effect in lupus nephritis treatments and explores future avenues for research, including CAR-T therapies and bispecific T-cell engagers.



Furthermore, he discusses the complexities of regulatory pathways in lupus studies, emphasizing the importance of collaboration among academia, industry, and regulatory bodies to foster advancements in treatment options. Furie's insights underscore the ongoing evolution and challenges of lupus research and patient care, ultimately calling for continued innovation and critical discussions around emerging therapies.

Specialties